-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical News, April 2nd.
Multinational pharmaceutical companies are generally more practical.
According to their own development strategies, they consciously divest some "old" non-profitable businesses and seek to develop new profit growth points.
Multinational pharmaceutical companies are generally more practical.
According to their own development strategies, they consciously divest some "old" non-profitable businesses and seek to develop new profit growth points.
Over 130 medicines were sold
Yesterday (March 31), Japan's Osaka-Takeda Pharmaceutical Co.
, Ltd.
(hereinafter referred to as "Takeda") announced the completion of the previously announced sales of selected product portfolios to Orifarm Group ("Orifarm"), with a total value of US$670 million.
The product portfolio includes approximately 130 over-the-counter ( OTC ) and prescription drug products sold in Europe , as well as two production sites in Denmark and Poland.
This divestment agreement was first announced in April 2020.
, Ltd.
(hereinafter referred to as "Takeda") announced the completion of the previously announced sales of selected product portfolios to Orifarm Group ("Orifarm"), with a total value of US$670 million.
The product portfolio includes approximately 130 over-the-counter ( OTC ) and prescription drug products sold in Europe , as well as two production sites in Denmark and Poland.
This divestment agreement was first announced in April 2020.
The divested product portfolio includes OTC products and food supplements, as well as selected products in the fields of cardiovascular, anti-inflammatory, respiratory and endocrine therapy, which are mainly sold to Denmark, Norway, Belgium, Poland, Finland, Sweden, the Baltic Sea and Austria.
The product portfolio, driven by cough/cold and vitamin OTC brands, as well as prescription drugs such as Warfarub and Levaxin, and other strong regional brands, generated approximately US$240 million in net sales for fiscal year 2020.
The product portfolio, driven by cough/cold and vitamin OTC brands, as well as prescription drugs such as Warfarub and Levaxin, and other strong regional brands, generated approximately US$240 million in net sales for fiscal year 2020.
As previously announced, Takeda and Orifarm have also reached a manufacturing and supply agreement under which Takeda will continue to manufacture products on behalf of Orifarm.
In addition, approximately 600 employees from the manufacturing plant, sales and marketing professionals, and the portfolio and manufacturing plant supporting the divestiture have transitioned to Orifarm.
In addition, approximately 600 employees from the manufacturing plant, sales and marketing professionals, and the portfolio and manufacturing plant supporting the divestiture have transitioned to Orifarm.
To some extent, Takeda has implemented the "sell, sell, sell" strategy of weight-loss.
Since the successful acquisition of Shire for $62 billion in 2019, the industry believes that the financial risks faced by Takeda have forced it to continue to sell its own assets.
It is reported that Takeda has surpassed its goal of divesting US$10 billion in non-core assets and has announced 12 transactions since January 2019, with a total value of US$12.
9 billion.
Since the successful acquisition of Shire for $62 billion in 2019, the industry believes that the financial risks faced by Takeda have forced it to continue to sell its own assets.
It is reported that Takeda has surpassed its goal of divesting US$10 billion in non-core assets and has announced 12 transactions since January 2019, with a total value of US$12.
9 billion.
Weight loss, outsourcing, and product abandonment become the main theme
Takeda is just a microcosm of many large multinational pharmaceutical companies—especially in China, where multinational pharmaceutical companies frequently outsource and divest their products: With the expiration of patent protection for original products of multinational pharmaceutical companies and the impact of Chinese local R&D companies, imitation Pharmaceuticals have drastically cut prices to compete for the original research drug market, and the sales of foreign companies' original research drugs in the Chinese market have slowed down.
Cyberlan has learned that in China, due to the advancement of consistency evaluation, over-reviewed generic drugs have created a new competitive landscape.
Coupled with the price reduction of mass procurement, foreign pharmaceutical companies are not only laying off employees, but also abandoning products.
Coupled with the price reduction of mass procurement, foreign pharmaceutical companies are not only laying off employees, but also abandoning products.
In fact, in order to save costs, focus on core areas, and improve the efficiency of resource utilization, foreign companies focus their efforts on innovative drugs that are not easy to be imitated by stripping products and transferring sales rights.
Invisibly, this gives domestic pharmaceutical companies more opportunities.
They can supplement their product lines and strengthen their competitive areas.
With the help of foreign companies' products with high brand recognition, they can expand their cash flow and enhance their competitiveness.
Invisibly, this gives domestic pharmaceutical companies more opportunities.
They can supplement their product lines and strengthen their competitive areas.
With the help of foreign companies' products with high brand recognition, they can expand their cash flow and enhance their competitiveness.
For example, on March 29, Baiyang Pharmaceutical and Roche Pharmaceuticals signed a strategic cooperation agreement.
Roche Pharmaceuticals will combine its two major oncology drug products Xeloda® (capecitabine tablets) and Tarceva® (erlotinib hydrochloride tablets) The marketing right in Mainland China was granted to Baiyang Pharmaceutical.
Roche Pharmaceuticals will combine its two major oncology drug products Xeloda® (capecitabine tablets) and Tarceva® (erlotinib hydrochloride tablets) The marketing right in Mainland China was granted to Baiyang Pharmaceutical.
If it is said that the promotion rights are transferred, foreign pharmaceutical companies still have the right to control the products.
Many multinational pharmaceutical companies are even more straightforward.
They simply lose weight and give up products.
Many multinational pharmaceutical companies are even more straightforward.
They simply lose weight and give up products.
For example, Bayer sold or divested the three major business segments of animal health, crop science, and consumer health ; more than a year after announcing the divestiture of the generic drug business, Mylan NV and Pfizer Upjohn, a business unit of Pfizer, succeeded After the merger, Huizhi Company was formally established on November 16, 2020.
This is a typical sign.
Since then, Pfizer has successfully discarded the generic drug business unit and focused on the biopharmaceutical business.
Since then, Pfizer has successfully discarded the generic drug business unit and focused on the biopharmaceutical business.
While losing weight, focus on innovative drugs
From Takeda’s acquisition of Shire and its successful ranking among the top 10 global pharmaceutical companies, it can be seen that the "division, division, and integration" among multinational pharmaceutical companies is commonplace, and mergers and sales in the industry will become more frequent in the future.
The global ranking will also be updated continuously.
The global ranking will also be updated continuously.
However, large pharmaceutical companies are generally more practical.
They will consciously divest some "old" non-profitable businesses based on their own development strategies and seek to develop new profit growth points.
Among them, it is the consensus of the industry to focus on the field of first innovative drugs.
They will consciously divest some "old" non-profitable businesses based on their own development strategies and seek to develop new profit growth points.
Among them, it is the consensus of the industry to focus on the field of first innovative drugs.
It is understood that the first-in-class drugs bring huge potential benefits to enterprises , they are subject to less market competition, and there is less pressure from the government, public opinion, and supply and demand parties to reduce prices.
They will continue to attract the attention of the capital market; in addition, the first-in-class drugs are often It is the world's first, and the huge benefits it brings to the enterprise are also reflected in the returns of the global market.
They will continue to attract the attention of the capital market; in addition, the first-in-class drugs are often It is the world's first, and the huge benefits it brings to the enterprise are also reflected in the returns of the global market.
According to data from the Pharmaceutical Research and Development Industry Committee (RDPAC) of the China Association of Enterprises with Foreign Investment, between 2016 and 2020, a total of 200 new drugs have been listed in China, 80% of which come from foreign innovative pharmaceutical companies.
From dyconine and astemizine, which are familiar to the public, to PD-1, which is known as the "anti-cancer drug", multinational pharmaceutical companies dedicated to the continuous research and development of innovative drugs, through innovative products such as hepatitis B vaccine, have gained a lot in China.
Big sales growth.
From dyconine and astemizine, which are familiar to the public, to PD-1, which is known as the "anti-cancer drug", multinational pharmaceutical companies dedicated to the continuous research and development of innovative drugs, through innovative products such as hepatitis B vaccine, have gained a lot in China.
Big sales growth.
On the whole, relevant departments control China's overall drug expenditures through different pharmaceutical procurement policies : The National Medical Insurance Catalogue ushered in the latest update at the end of 2020, and it is expected that the innovative drugs used in the catalogue will promote significant growth in the performance of innovative drug companies.
With the reform of the procurement model of volume-for-price procurement, generic pharmaceutical companies will usher in more fierce competition, which will further promote foreign-funded pharmaceutical companies to divest original research products and tilt resources in the field of innovation.
With the reform of the procurement model of volume-for-price procurement, generic pharmaceutical companies will usher in more fierce competition, which will further promote foreign-funded pharmaceutical companies to divest original research products and tilt resources in the field of innovation.
Medical News, April 2nd.
Multinational pharmaceutical companies are generally more practical.
According to their own development strategies, they consciously divest some "old" non-profitable businesses and seek to develop new profit growth points.
Multinational pharmaceutical companies are generally more practical.
According to their own development strategies, they consciously divest some "old" non-profitable businesses and seek to develop new profit growth points.
Over 130 medicines were sold
Yesterday (March 31), Japan's Osaka-Takeda Pharmaceutical Co.
, Ltd.
(hereinafter referred to as "Takeda") announced the completion of the previously announced sales of selected product portfolios to Orifarm Group ("Orifarm"), with a total value of US$670 million.
The product portfolio includes approximately 130 over-the-counter ( OTC ) and prescription drug products sold in Europe , as well as two production sites in Denmark and Poland.
This divestment agreement was first announced in April 2020.
, Ltd.
(hereinafter referred to as "Takeda") announced the completion of the previously announced sales of selected product portfolios to Orifarm Group ("Orifarm"), with a total value of US$670 million.
The product portfolio includes approximately 130 over-the-counter ( OTC ) and prescription drug products sold in Europe , as well as two production sites in Denmark and Poland.
This divestment agreement was first announced in April 2020.
The divested product portfolio includes OTC products and food supplements, as well as selected products in the fields of cardiovascular, anti-inflammatory, respiratory and endocrine therapy, which are mainly sold to Denmark, Norway, Belgium, Poland, Finland, Sweden, the Baltic Sea and Austria.
The product portfolio, driven by cough/cold and vitamin OTC brands, as well as prescription drugs such as Warfarub and Levaxin, and other strong regional brands, generated approximately US$240 million in net sales for fiscal year 2020.
The product portfolio, driven by cough/cold and vitamin OTC brands, as well as prescription drugs such as Warfarub and Levaxin, and other strong regional brands, generated approximately US$240 million in net sales for fiscal year 2020.
As previously announced, Takeda and Orifarm have also reached a manufacturing and supply agreement under which Takeda will continue to manufacture products on behalf of Orifarm.
In addition, approximately 600 employees from the manufacturing plant, sales and marketing professionals, and the portfolio and manufacturing plant supporting the divestiture have transitioned to Orifarm.
In addition, approximately 600 employees from the manufacturing plant, sales and marketing professionals, and the portfolio and manufacturing plant supporting the divestiture have transitioned to Orifarm.
To some extent, Takeda has implemented the "sell, sell, sell" strategy of weight-loss.
Since the successful acquisition of Shire for $62 billion in 2019, the industry believes that the financial risks faced by Takeda have forced it to continue to sell its own assets.
It is reported that Takeda has surpassed its goal of divesting US$10 billion in non-core assets and has announced 12 transactions since January 2019, with a total value of US$12.
9 billion.
Since the successful acquisition of Shire for $62 billion in 2019, the industry believes that the financial risks faced by Takeda have forced it to continue to sell its own assets.
It is reported that Takeda has surpassed its goal of divesting US$10 billion in non-core assets and has announced 12 transactions since January 2019, with a total value of US$12.
9 billion.
Weight loss, outsourcing, and product abandonment become the main theme
Takeda is just a microcosm of many large multinational pharmaceutical companies—especially in China, where multinational pharmaceutical companies frequently outsource and divest their products: With the expiration of patent protection for original products of multinational pharmaceutical companies and the impact of Chinese local R&D companies, imitation Pharmaceuticals have drastically cut prices to compete for the original research drug market, and the sales of foreign companies' original research drugs in the Chinese market have slowed down.
Cyberlan has learned that in China, due to the advancement of consistency evaluation, over-reviewed generic drugs have created a new competitive landscape.
Coupled with the price reduction of mass procurement, foreign pharmaceutical companies are not only laying off employees, but also abandoning products.
Coupled with the price reduction of mass procurement, foreign pharmaceutical companies are not only laying off employees, but also abandoning products.
In fact, in order to save costs, focus on core areas, and improve the efficiency of resource utilization, foreign companies focus their efforts on innovative drugs that are not easy to be imitated by stripping products and transferring sales rights.
Invisibly, this gives domestic pharmaceutical companies more opportunities.
They can supplement their product lines and strengthen their competitive areas.
With the help of foreign companies' products with high brand recognition, they can expand their cash flow and enhance their competitiveness.
Invisibly, this gives domestic pharmaceutical companies more opportunities.
They can supplement their product lines and strengthen their competitive areas.
With the help of foreign companies' products with high brand recognition, they can expand their cash flow and enhance their competitiveness.
For example, on March 29, Baiyang Pharmaceutical and Roche Pharmaceuticals signed a strategic cooperation agreement.
Roche Pharmaceuticals will combine its two major oncology drug products Xeloda® (capecitabine tablets) and Tarceva® (erlotinib hydrochloride tablets) The marketing right in Mainland China was granted to Baiyang Pharmaceutical.
Roche Pharmaceuticals will combine its two major oncology drug products Xeloda® (capecitabine tablets) and Tarceva® (erlotinib hydrochloride tablets) The marketing right in Mainland China was granted to Baiyang Pharmaceutical.
If it is said that the promotion rights are transferred, foreign pharmaceutical companies still have the right to control the products.
Many multinational pharmaceutical companies are even more straightforward.
They simply lose weight and give up products.
Many multinational pharmaceutical companies are even more straightforward.
They simply lose weight and give up products.
For example, Bayer sold or divested the three major business segments of animal health, crop science, and consumer health ; more than a year after announcing the divestiture of the generic drug business, Mylan NV and Pfizer Upjohn, a business unit of Pfizer, succeeded After the merger, Huizhi Company was formally established on November 16, 2020.
This is a typical sign.
Since then, Pfizer has successfully discarded the generic drug business unit and focused on the biopharmaceutical business.
Since then, Pfizer has successfully discarded the generic drug business unit and focused on the biopharmaceutical business.
While losing weight, focus on innovative drugs
From Takeda’s acquisition of Shire and its successful ranking among the top 10 global pharmaceutical companies, it can be seen that the "division, division, and integration" among multinational pharmaceutical companies is commonplace, and mergers and sales in the industry will become more frequent in the future.
The global ranking will also be updated continuously.
The global ranking will also be updated continuously.
However, large pharmaceutical companies are generally more practical.
They will consciously divest some "old" non-profitable businesses based on their own development strategies and seek to develop new profit growth points.
Among them, it is the consensus of the industry to focus on the field of first innovative drugs.
They will consciously divest some "old" non-profitable businesses based on their own development strategies and seek to develop new profit growth points.
Among them, it is the consensus of the industry to focus on the field of first innovative drugs.
It is understood that the first-in-class drugs bring huge potential benefits to enterprises , they are subject to less market competition, and there is less pressure from the government, public opinion, and supply and demand parties to reduce prices.
They will continue to attract the attention of the capital market; in addition, the first-in-class drugs are often It is the world's first, and the huge benefits it brings to the enterprise are also reflected in the returns of the global market.
They will continue to attract the attention of the capital market; in addition, the first-in-class drugs are often It is the world's first, and the huge benefits it brings to the enterprise are also reflected in the returns of the global market.
According to data from the Pharmaceutical Research and Development Industry Committee (RDPAC) of the China Association of Enterprises with Foreign Investment, between 2016 and 2020, a total of 200 new drugs have been listed in China, 80% of which come from foreign innovative pharmaceutical companies.
From dyconine and astemizine, which are familiar to the public, to PD-1, which is known as the "anti-cancer drug", multinational pharmaceutical companies dedicated to the continuous research and development of innovative drugs, through innovative products such as hepatitis B vaccine, have gained a lot in China.
Big sales growth.
From dyconine and astemizine, which are familiar to the public, to PD-1, which is known as the "anti-cancer drug", multinational pharmaceutical companies dedicated to the continuous research and development of innovative drugs, through innovative products such as hepatitis B vaccine, have gained a lot in China.
Big sales growth.
On the whole, relevant departments control China's overall drug expenditures through different pharmaceutical procurement policies : The National Medical Insurance Catalogue ushered in the latest update at the end of 2020, and it is expected that the innovative drugs used in the catalogue will promote significant growth in the performance of innovative drug companies.
With the reform of the procurement model of volume-for-price procurement, generic pharmaceutical companies will usher in more fierce competition, which will further promote foreign-funded pharmaceutical companies to divest original research products and tilt resources in the field of innovation.
With the reform of the procurement model of volume-for-price procurement, generic pharmaceutical companies will usher in more fierce competition, which will further promote foreign-funded pharmaceutical companies to divest original research products and tilt resources in the field of innovation.
Medical News, April 2nd.
Multinational pharmaceutical companies are generally more practical.
According to their own development strategies, they consciously divest some "old" non-profitable businesses and seek to develop new profit growth points.
Multinational pharmaceutical companies are generally more practical.
According to their own development strategies, they consciously divest some "old" non-profitable businesses and seek to develop new profit growth points.
Over 130 medicines were sold
Over 130 medicines were sold Yesterday (March 31), Japan's Osaka-Takeda Pharmaceutical Co.
, Ltd.
(hereinafter referred to as "Takeda") announced the completion of the previously announced sales of selected product portfolios to Orifarm Group ("Orifarm"), with a total value of US$670 million.
The product portfolio includes approximately 130 over-the-counter ( OTC ) and prescription drug products sold in Europe , as well as two production sites in Denmark and Poland.
This divestment agreement was first announced in April 2020.
OTC OTC, Ltd.
(hereinafter referred to as "Takeda") announced the completion of the previously announced sales of selected product portfolios to Orifarm Group ("Orifarm"), with a total value of US$670 million.
The product portfolio includes approximately 130 over-the-counter ( OTC ) and prescription drug products sold in Europe , as well as two production sites in Denmark and Poland.
This divestment agreement was first announced in April 2020.
The divested product portfolio includes OTC products and food supplements, as well as selected products in the fields of cardiovascular, anti-inflammatory, respiratory and endocrine therapy, which are mainly sold to Denmark, Norway, Belgium, Poland, Finland, Sweden, the Baltic Sea and Austria.
The product portfolio, driven by cough/cold and vitamin OTC brands, as well as prescription drugs such as Warfarub and Levaxin, and other strong regional brands, generated approximately US$240 million in net sales for fiscal year 2020.
The product portfolio, driven by cough/cold and vitamin OTC brands, as well as prescription drugs such as Warfarub and Levaxin, and other strong regional brands, generated approximately US$240 million in net sales for fiscal year 2020.
As previously announced, Takeda and Orifarm have also reached a manufacturing and supply agreement under which Takeda will continue to manufacture products on behalf of Orifarm.
In addition, approximately 600 employees from the manufacturing plant, sales and marketing professionals, and the portfolio and manufacturing plant supporting the divestiture have transitioned to Orifarm.
In addition, approximately 600 employees from the manufacturing plant, sales and marketing professionals, and the portfolio and manufacturing plant supporting the divestiture have transitioned to Orifarm.
To some extent, Takeda has implemented the "sell, sell, sell" strategy of weight-loss.
Since the successful acquisition of Shire for $62 billion in 2019, the industry believes that the financial risks faced by Takeda have forced it to continue to sell its own assets.
It is reported that Takeda has surpassed its goal of divesting US$10 billion in non-core assets and has announced 12 transactions since January 2019, with a total value of US$12.
9 billion.
Since the successful acquisition of Shire for $62 billion in 2019, the industry believes that the financial risks faced by Takeda have forced it to continue to sell its own assets.
It is reported that Takeda has surpassed its goal of divesting US$10 billion in non-core assets and has announced 12 transactions since January 2019, with a total value of US$12.
9 billion.
Weight loss, outsourcing, and product abandonment become the main theme
Weight loss, outsourcing, and product abandonment become the main theme Takeda is just a microcosm of many large multinational pharmaceutical companies—especially in China, where multinational pharmaceutical companies frequently outsource and divest their products: With the expiration of patent protection for original products of multinational pharmaceutical companies and the impact of Chinese local R&D companies, imitation Pharmaceuticals have drastically cut prices to compete for the original research drug market, and the sales of foreign companies' original research drugs in the Chinese market have slowed down.
Cyberlan has learned that in China, due to the advancement of consistency evaluation, over-reviewed generic drugs have created a new competitive landscape.
Coupled with the price reduction of mass procurement, foreign pharmaceutical companies are not only laying off employees, but also abandoning products.
Coupled with the price reduction of mass procurement, foreign pharmaceutical companies are not only laying off employees, but also abandoning products.
In fact, in order to save costs, focus on core areas, and improve the efficiency of resource utilization, foreign companies focus their efforts on innovative drugs that are not easy to be imitated by stripping products and transferring sales rights.
Invisibly, this gives domestic pharmaceutical companies more opportunities.
They can supplement their product lines and strengthen their competitive areas.
With the help of foreign companies' products with high brand recognition, they can expand their cash flow and enhance their competitiveness.
Invisibly, this gives domestic pharmaceutical companies more opportunities.
They can supplement their product lines and strengthen their competitive areas.
With the help of foreign companies' products with high brand recognition, they can expand their cash flow and enhance their competitiveness.
For example, on March 29, Baiyang Pharmaceutical and Roche Pharmaceuticals signed a strategic cooperation agreement.
Roche Pharmaceuticals will combine its two major oncology drug products Xeloda® (capecitabine tablets) and Tarceva® (erlotinib hydrochloride tablets) The marketing right in Mainland China was granted to Baiyang Pharmaceutical.
Medicine Medicine MedicineRoche Pharmaceuticals will combine its two major oncology drug products Xeloda® (capecitabine tablets) and Tarceva® (erlotinib hydrochloride tablets) The marketing right in Mainland China was granted to Baiyang Pharmaceutical.
If it is said that the promotion rights are transferred, foreign pharmaceutical companies still have the right to control the products.
Many multinational pharmaceutical companies are even more straightforward.
They simply lose weight and give up products.
Many multinational pharmaceutical companies are even more straightforward.
They simply lose weight and give up products.
For example, Bayer sold or divested the three major business segments of animal health, crop science, and consumer health ; more than a year after announcing the divestiture of the generic drug business, Mylan NV and Pfizer Upjohn, a business unit of Pfizer, succeeded After the merger, Huizhi Company was formally established on November 16, 2020.
Healthy, healthy, healthy This is a typical sign.
Since then, Pfizer has successfully discarded the generic drug business unit and focused on the biopharmaceutical business.
Since then, Pfizer has successfully discarded the generic drug business unit and focused on the biopharmaceutical business.
While losing weight, focus on innovative drugs
While losing weight, focus on innovative drugs From Takeda’s acquisition of Shire and its successful ranking among the top 10 global pharmaceutical companies, it can be seen that the "division, division, and integration" among multinational pharmaceutical companies is commonplace, and mergers and sales in the industry will become more frequent in the future.
The global ranking will also be updated continuously.
The global ranking will also be updated continuously.
However, large pharmaceutical companies are generally more practical.
They will consciously divest some "old" non-profitable businesses based on their own development strategies and seek to develop new profit growth points.
Among them, it is the consensus of the industry to focus on the field of first innovative drugs.
They will consciously divest some "old" non-profitable businesses based on their own development strategies and seek to develop new profit growth points.
Among them, it is the consensus of the industry to focus on the field of first innovative drugs.
It is understood that the first-in-class drugs bring huge potential benefits to enterprises , they are subject to less market competition, and there is less pressure from the government, public opinion, and supply and demand parties to reduce prices.
They will continue to attract the attention of the capital market; in addition, the first-in-class drugs are often It is the world's first, and the huge benefits it brings to the enterprise are also reflected in the returns of the global market.
Enterprise business enterpriseThey will continue to attract the attention of the capital market; in addition, the first-in-class drugs are often It is the world's first, and the huge benefits it brings to the enterprise are also reflected in the returns of the global market.
According to data from the Pharmaceutical Research and Development Industry Committee (RDPAC) of the China Association of Enterprises with Foreign Investment, between 2016 and 2020, a total of 200 new drugs have been listed in China, 80% of which come from foreign innovative pharmaceutical companies.
From dyconine and astemizine, which are familiar to the public, to PD-1, which is known as the "anti-cancer drug", multinational pharmaceutical companies dedicated to the continuous research and development of innovative drugs, through innovative products such as hepatitis B vaccine, have gained a lot in China.
Big sales growth.
From dyconine and astemizine, which are familiar to the public, to PD-1, which is known as the "anti-cancer drug", multinational pharmaceutical companies dedicated to the continuous research and development of innovative drugs, through innovative products such as hepatitis B vaccine, have gained a lot in China.
Big sales growth.
On the whole, relevant departments control China's overall drug expenditures through different pharmaceutical procurement policies : The National Medical Insurance Catalogue ushered in the latest update at the end of 2020, and it is expected that the innovative drugs used in the catalogue will promote significant growth in the performance of innovative drug companies.
With the reform of the procurement model of volume-for-price procurement, generic pharmaceutical companies will usher in more fierce competition, which will further promote foreign-funded pharmaceutical companies to divest original research products and tilt resources in the field of innovation.
Medicine, medicine, medicine With the reform of the procurement model of volume-for-price procurement, generic pharmaceutical companies will usher in more fierce competition, which will further promote foreign-funded pharmaceutical companies to divest original research products and tilt resources in the field of innovation.
